{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.4","spread":"7.4","upperLimit":"9.2","value":"8.9"},{"groupId":"OG001","lowerLimit":"3.6","spread":"3.6","upperLimit":"5.4","value":"3.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"478"},{"groupId":"OG001","value":"476"}],"units":"Participants"}],"description":"TTP was defined as the time from the date of randomization to the date of first documentation of disease progression based on mRECIST. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the subject's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"OG000","title":"Lenvatinib"},{"description":"Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"OG001","title":"Sorafenib"}],"paramType":"MEDIAN","populationDescription":"The FAS included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"The time from the date of randomization to the date of first documentation of disease progression (approximately up to 3.8 years)","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}